Viatris 2023 Sustainability Report: Breaking Down Systemic Barriers To Access Through Policy Engagement
Viatris, a global pharmaceutical company, released its 2023 Sustainability Report highlighting efforts to break down systemic barriers to medicine access through policy engagement. As a member of ~160 trade associations, Viatris leverages its global experience and expertise to support policymakers in developing policies that advance access to quality medicines.
Key initiatives in 2023 included:
- Advancing regulatory harmonization through participation in International Council on Harmonization (ICH) working groups
- Supporting the UK's Windsor Framework to protect post-Brexit medicine access
- Partnering with the Center for Research on Complex Generics in the U.S.
- Assessing localization policies' impact on medicine access
- Engaging in the European Pharmaceutical Legislation revision
- Supporting studies on healthcare investment and innovative financing for Universal Health Coverage
Viatris' global policy priorities focus on advancing access to quality medicines, strengthening resilient global supply, and building future access across diverse therapeutic areas and geographies.
Viatris, un'azienda farmaceutica globale, ha pubblicato il suo Rapporto di Sostenibilità 2023 evidenziando gli sforzi per abbattere le barriere sistemiche all'accesso ai medicinali attraverso un impegno politico. In quanto membro di circa 160 associazioni di categoria, Viatris sfrutta la propria esperienza e competenza globale per supportare i decisori politici nello sviluppo di politiche che migliorano l'accesso a medicinali di qualità.
Le principali iniziative nel 2023 includevano:
- Promuovere l'armonizzazione normativa attraverso la partecipazione a gruppi di lavoro dell'International Council on Harmonization (ICH)
- Supportare il Windsor Framework del Regno Unito per proteggere l'accesso ai medicinali post-Brexit
- Collaborare con il Center for Research on Complex Generics negli Stati Uniti
- Valutare l'impatto delle politiche di localizzazione sull'accesso ai medicinali
- Partecipare alla revisione della Legislazione Farmaceutica Europea
- Supportare studi sugli investimenti in sanità e sul finanziamento innovativo per la Copertura Sanitaria Universale
Le priorità politiche globali di Viatris si concentrano sul miglioramento dell'accesso a medicinali di qualità, sul rafforzamento di una rete di approvvigionamento globale resiliente e sulla costruzione di un accesso futuro in diverse aree terapeutiche e geografiche.
Viatris, una compañía farmacéutica global, ha publicado su Informe de Sostenibilidad 2023 resaltando los esfuerzos para desmantelar las barreras sistémicas al acceso a medicamentos a través del compromiso político. Como miembro de aproximadamente 160 asociaciones comerciales, Viatris aprovecha su experiencia y conocimiento global para apoyar a los formuladores de políticas en el desarrollo de políticas que mejoren el acceso a medicamentos de calidad.
Las iniciativas clave en 2023 incluyeron:
- Avanzar en la armonización regulatoria mediante la participación en grupos de trabajo del International Council on Harmonization (ICH)
- Apoyar el Windsor Framework del Reino Unido para proteger el acceso a medicamentos tras el Brexit
- Colaborar con el Center for Research on Complex Generics en EE. UU.
- Evaluar el impacto de las políticas de localización en el acceso a medicamentos
- Participar en la revisión de la Legislación Farmacéutica Europea
- Apoyar estudios sobre la inversión en salud y financiamiento innovador para la Cobertura Sanitaria Universal
Las prioridades de política global de Viatris se centran en mejorar el acceso a medicamentos de calidad, fortalecer una cadena de suministro global resiliente y construir un acceso futuro en diversas áreas terapéuticas y geografías.
Viatris는 글로벌 제약회사로서 2023 지속 가능성 보고서를 발행하며 정책 참여를 통해 의약품 접근에 대한 시스템적 장벽을 허물기 위한 노력을 강조했습니다. Viatris는 약 160개의 무역 협회의 일원으로서, 전 세계의 경험과 전문성을 활용하여 정책 입안자들이 품질 있는 의약품 접근을 증진하는 정책을 개발할 수 있도록 지원합니다.
2023년의 주요 이니셔티브는 다음과 같습니다:
- 국제조화위원회(ICH) 작업 그룹에 참여하여 규제 조화를 추진
- 브렉시트 이후 의약품 접근을 보호하기 위한 영국의 윈저 프레임워크 지원
- 미국의 복합 제네릭 연구 센터와의 파트너십
- 의약품 접근에 대한 지역화 정책의 영향 평가
- 유럽 제약 법률 개정 참여
- 보편적 건강 보장을 위한 건강 투자 및 혁신적 자금 조달에 대한 연구 지원
Viatris의 글로벌 정책 우선 사항은 품질 있는 의약품 접근 증진, 강력한 글로벌 공급망 강화 및 다양한 치료 분야와 지역에서의 미래 접근성 구축에 중점을 두고 있습니다.
Viatris, une entreprise pharmaceutique mondiale, a publié son Rapport de Durabilité 2023 mettant en avant ses efforts pour briser les barrières systémiques à l'accès aux médicaments grâce à un engagement politique. En tant que membre de près de 160 associations professionnelles, Viatris utilise son expérience et son expertise mondiale pour soutenir les décideurs dans le développement de politiques qui avancent l'accès à des médicaments de qualité.
Les initiatives clés de 2023 comprenaient :
- Avancer l'harmonisation réglementaire en participant à des groupes de travail de l'International Council on Harmonization (ICH)
- Soutenir le Windsor Framework du Royaume-Uni pour protéger l'accès aux médicaments après le Brexit
- Collaborer avec le Center for Research on Complex Generics aux États-Unis
- Évaluer l'impact des politiques de localisation sur l'accès aux médicaments
- Participer à la révision de la législation pharmaceutique européenne
- Soutenir des études sur les investissements en santé et le financement innovant pour la couverture santé universelle
Les priorités politiques mondiales de Viatris se concentrent sur l'amélioration de l'accès aux médicaments de qualité, le renforcement d'une chaîne d'approvisionnement mondiale résiliente et la construction d'un accès futur dans diverses zones thérapeutiques et géographiques.
Viatris, ein globales Pharmaunternehmen, hat seinen Nachhaltigkeitsbericht 2023 veröffentlicht, der die Bemühungen hervorhebt, systematische Barrieren beim Zugang zu Medikamenten durch politische Engagement abzubauen. Als Mitglied von ca. 160 Handelsverbänden nutzt Viatris seine globale Erfahrung und Expertise, um politische Entscheidungsträger bei der Entwicklung von Politiken zu unterstützen, die den Zugang zu hochwertigen Medikamenten fördern.
Zu den wichtigsten Initiativen im Jahr 2023 gehörten:
- Förderung der regulatorischen Harmonisierung durch die Teilnahme an Arbeitsgruppen des International Council on Harmonization (ICH)
- Unterstützung des Windsor Frameworks im Vereinigten Königreich zum Schutz des Zugangs zu Medikamenten nach dem Brexit
- Partnerschaft mit dem Center for Research on Complex Generics in den USA
- Bewertung der Auswirkungen von Lokalisierungspolitiken auf den Zugang zu Medikamenten
- Engagement bei der Überarbeitung der europäischen Arzneimittelgesetzgebung
- Unterstützung von Studien zu Gesundheitsinvestitionen und innovativer Finanzierung für die universelle Gesundheitsversorgung
Die globalen politischen Prioritäten von Viatris konzentrieren sich auf die Verbesserung des Zugangs zu hochwertigen Medikamenten, die Stärkung einer resilienten globalen Versorgung und den Aufbau zukünftigen Zugangs in verschiedenen therapeutischen Bereichen und Geografien.
- None.
- None.
NORTHAMPTON, MA / ACCESSWIRE / September 9, 2024 / Over the course of their lifetime, people will likely need many types of medicine, spanning infectious and noncommunicable diseases (NCDs). Accessing all these medicines at the right time, in the right place, can be life changing. Public policies are central factors in determining access to medicines as most often there are systemic issues that need to be addressed for meaningful and lasting improvements. Moreover, policymakers often encounter increasingly complex environments where finding perfect solutions is challenging.
Viatris is a member of ~160 trade associations.
We leverage our global experiences, scientific expertise and operations knowledge to support policymakers in identifying policies that advance access to quality medicines and build systems that sustain availability while minimizing unintended consequences. Because we have operations in countries around the world and a broad portfolio across most therapeutic areas spanning generics, trusted brands, improved versions of existing medicines and novel therapeutics, we have insights into the trade-offs policymakers face when considering how best to develop policies that meet people's diverse health needs.
Given the breadth of our portfolio and geographic footprint, Viatris is well positioned to support policymakers in identifying opportunities for policy change aligned with advancing access to medicines - not just for one medicine, or one disease, but for all medicines. Taking a systems-level approach to consider policy enablers of access allows us to identify the changes that could facilitate access, not only for one company, but for all seeking to serve the world's health needs.
Our global policy priorities are to advance access to quality medicines, strengthen resilient global supply and build future access. In 2023, we did this in many ways including:
Advancing Access to Quality Medicines
Engaged alongside industry partners including the International Generic and Biosimilar Medicines Association (IGBA) in pursuit of regulatory harmonization, including actively contributing expertise to technical working groups of the International Council on Harmonization (ICH). Through IGBA, Viatris has a strong presence on ICH Expert Working Groups (EWGs). Viatris currently represents IGBA on four ICH EWGs, providing our technical expertise to help increase harmonization worldwide for the development and approval of safe, effective, and high-quality medicines.
Supported the UK's Windsor Framework, an agreement that helps protect access to medicine post-Brexit.
In the U.S., Viatris partnered closely with the Center for Research on Complex Generics (CRCG), which facilitates research and collaborations across industry, academia and the FDA to increase access to safe and effective generic drugs, sharing our expertise on topics ranging from complex excipients to drug device combination products.
Sponsored EURACTIV's European Special Report to help regulators and other stakeholders understand the causes of medicine shortages and help to build solutions that are targeted and effective, including harmonizing regulatory requirements and replacing paper patient information leaflets with e-leaflets to allow for label changes without the need to repackage products.
Strengthening Resilient Global Supply
Joined with industry stakeholders and Charles River Associates to assess the interplay of localization policies and access to medicines.
Working closely with our trade association in Australia, Viatris is helping to drive changes with e-labeling. The Australian regulator has updated its guidance on requiring pack inserts for injectable products administered by a HCP, so Viatris is working to remove paper leaflets where possible and replace them with QR codes on packs.
Provided feedback to relevant agencies and institutions as they consider solutions to drug shortages.
Made recommendations to the Australia House of Representatives Inquiry into developing local manufacturing capabilities, including revisions that would better enable generic medicines to be manufactured for export. These changes could improve Australia's ability to supply critical medicines to countries in need, leveraging its manufacturing capabilities to contribute to global access.
Building Sustainable Healthcare Systems and Future Access
Actively engaged in the European Pharmaceutical Legislation revision, which proposes to include a focus on creating relevant pathways for repurposed medicines in Europe and continue to engage in dialogue to consider broadening this proposal to include additional types of medicine improvements
Contributed to the paper "Unlocking barriers to scale Innovative Financing for Universal Health Coverage," which was launched in 2023 by the U.S. Chamber of Commerce to explore new ways to grow and sustain healthcare financing and highlight the important role the private sector can play in innovative finance mechanisms
Supported a study by the University of Athens (IPOKE Research Institute) which found that chronic underinvestment in healthcare in Eastern and Southern European countries over the past two decades has resulted in significantly lower healthy life years for the citizens of these countries compared to the rest of the Europe. The impact of Underinvestment on Medicines and Health Services study identifies the urgent need for policy action to tackle health inequalities through increased healthcare investments, fostering a healthier future for all citizens across Europe, and avoiding disruptions in the healthcare and pharmaceutical sector.
Hosted STRIVE (Striving for Innovation, Value & Excellence in Pharmaceutical Procurement) in partnership with Galen Centre of Health and Social Policy, which brought together participants from government agencies, medical associations, the private sector and other stakeholders to discuss value-based healthcare and value-based procurement in Malaysia
Worked closely with industry associations in the Philippines including the US-ASEAN Business Council on the expansion of the Primary Care Benefit Package, known as the Konsulta Package. In November 2023, PHILHEALTH approved the inclusion of atorvastatin, celecoxib, and gabapentin (joining amlopidine) in the list of pre-approved medicines under the Outpatient Benefit Package under Konsulta. Now, primary care facilities can prescribe these medications and can be reimbursed under the PHILHEALTH package.
View the full 2023 Sustainability Report.
View additional multimedia and more ESG storytelling from Viatris on 3blmedia.com.
Contact Info:
Spokesperson: Viatris
Website: https://www.3blmedia.com/profiles/viatris
Email: info@3blmedia.com
SOURCE: Viatris
View the original press release on accesswire.com
FAQ
What were Viatris' (VTRS) key policy engagement initiatives in 2023?
How many trade associations is Viatris (VTRS) a member of?
What are Viatris' (VTRS) global policy priorities as outlined in the 2023 Sustainability Report?
How did Viatris (VTRS) contribute to addressing medicine shortages in 2023?
What initiative did Viatris (VTRS) support in Malaysia regarding healthcare procurement in 2023?
